TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Predictive Oncology ( (POAI) ) has shared an announcement.
At the Annual Meeting, Predictive Oncology‘s stockholders voted on several key proposals. The election of Class I directors, including Daniel E. Handley and Chuck Nuzum, was confirmed to serve until the 2028 Annual Meeting. Additionally, KPMG LLP’s appointment as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Stockholders also approved an amendment and the issuance of 14,903,393 shares upon the exercise of pre-funded warrants. Furthermore, a non-binding advisory vote approved the compensation of the company’s named executive officers.
The most recent analyst rating on (POAI) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.
Spark’s Take on POAI Stock
According to Spark, TipRanks’ AI Analyst, POAI is a Underperform.
The overall stock score is heavily impacted by significant financial challenges, including declining revenues and negative profit margins. Technical analysis indicates bearish momentum, and valuation metrics are unattractive due to ongoing losses. The absence of earnings call insights and corporate events does not alter the negative outlook.
To see Spark’s full report on POAI stock, click here.
More about Predictive Oncology
Average Trading Volume: 95,330
Technical Sentiment Signal: Sell
Current Market Cap: $21.21M
Learn more about POAI stock on TipRanks’ Stock Analysis page.